A5039594306- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pulmonary Hypertension Research and Treatments
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- PI3K/AKT/mTOR signaling in cancer
- Eicosanoids and Hypertension Pharmacology
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Head and Neck Cancer Studies
- Immune cells in cancer
- Testicular diseases and treatments
- Multiple Myeloma Research and Treatments
- Cardiovascular Issues in Pregnancy
- Cancer Diagnosis and Treatment
First Affiliated Hospital of Zhengzhou University
2022-2025
First Affiliated Hospital of Guangzhou Medical University
2022-2024
State Key Laboratory of Respiratory Disease
2022-2024
Guangzhou Medical University
2022-2024
Abstract HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively vascular endothelial growth factor receptor-2, receptor, fibroblast receptor 1-3. The safety, pharmacokinetics, efficacy of HA121-28 were assessed in advanced solid tumors (phase 1, ClinicalTrials.gov NCT03994484) RET fusion-positive non-small-cell lung cancer (RET-TKI naive NSCLC, phase 2, NCT05117658). was administered orally doses range from 25 to 800 mg under...
Introduction This retrospective study evaluates the efficacy of camrelizumab combined with anlotinib versus chemotherapy in patients extensive-stage small-cell lung cancer (ES-SCLC) undergoing second-line treatment. Methods Data were sourced from medical records at a Chinese facility, involving 34 diagnosed ES-SCLC after failing first-line Patients divided into two groups: one received (200 mg every 3 weeks) (12 daily for 14 days followed by 7-day rest), while other group physician-chosen...
Chronic thromboembolic pulmonary hypertension (CTEPH) is a vascular disease characterized by an insidious onset, progressive deterioration, and poor prognosis. It distinguished the thrombotic organization within arteries, leading to stenosis or occlusion. This results in increase resistance arterial pressure, ultimately right heart failure. In recent years, balloon angioplasty (BPA) has emerged as effective treatment option for patients ineligible endarterectomy (PEA). However, use of stents...
肝样腺癌是一种罕见的肝外恶性肿瘤，具有与肝细胞癌相似的形态学特征和组织学特征。其多发生于胃部，原发于肠道者较为罕见。本文报道1例肠道多原发性肝样腺癌的诊治过程，旨在为临床医师提供参考。.
<title>Abstract</title> REZOR is a multicenter, double-blinded, randomized phase 3 study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) gefitinib as first-line therapies in patients with EGFR mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC). The included eligible from 50 hospitals across China. Those who had been histologically cytologically confirmed NSCLC exon 19 deletion 21 L858R mutation by central laboratory were randomly assigned (1:1)...
Objective: To investigate the response characteristics of patients with locally advanced/metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) treated tislelizumab in combination chemotherapy first line. Methods: Patients nsq-NSCLC who achieved complete or partial remission after treatment alone RATIONALE 304 study, as assessed by an independent review board, were selected to analyze and safety profile responders. Time (TTR) was defined time from randomization achievement objective...
6027 Background: Penpulimab is a novel human immunoglobulin G1 (IgG1) anti-programmed cell death-1 (PD-1) antibody. The effect of antibody-dependent cell-mediated cytotoxicity and cellular phagocytosis was eliminated completely by the modification crystallizable fragment to avoid FcγR binding. ALTN-AK105-II-01 (NCT04203719) single-arm, multi-cohort, multicenter phase 2 study explore efficacy safety penpulimab plus anlotinib, multikinase inhibitor inhibiting angiogenesis tumor proliferation...